Another controversy that we will discuss here is the acceptance of adjuvant therapy for resected stage IB-IIIA non-small-cell lung cancer. It was not long ago that adjuvant radiation therapy was ...

Explore how adjuvant osimertinib aids in detecting molecular residual disease in resected EGFR-mutated NSCLC, offering ...

In the continuing evolution of personalized medicine, a new Yale study has found evidence to support the value of a tool that ...

Stage 3A lung cancer is considered regional, having spread beyond the lung. Treatment options include surgery, advanced drug therapies, chemotherapy, and radiation. In 2021, 209,500 people in the ...

31 study showed that giving Imfinzi (durvalumab) as adjuvant therapy for stage IB-IIIA non-small cell lung cancer (NSCLC) was no better than placebo at extending disease-free survival (DFS).

Exploratory post hoc analysis of molecular residual disease from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer shows ...

The introduction of new agents for the treatment of lung cancer has also brought with it the expectation for greater activity, which may also lead to a downstaging of bulky tumors and enable the ...

Lung cancer arises in tissues of the lung, usually in the cells lining air passages. The two main types are small-cell lung cancer and non-small-cell lung cancer, according to the shape of cells ...